goat anti-human PAI-2 IgG
Description
Plasminogen Activator Inhibitor Type 2 (PAI-2) is one of two endogenous inhibitors of urokinase-type plasminogen activator (urokinase, uPA). PAI-2 is a member of the serpin family of protease inhibitors. It exists as a 48 kDa non-glycosylated form found in placental tissue and a 60 kDa glycosylated secreted form found in maternal blood and ascitic fluid.
Generally PAI-2 is undetectable in the majority of peripheral blood samples. However levels of PAI-2 appear to be higher in patient´s ascitic fluid from malignant tumors, as compared to benign tumors (1). PAI-2 levels appear to increase during pregnancy, reaching 120-550 ng/mL in the third trimester (2, 3).
Preparation
From goats immunized with recombinant human PAI-2. The IgG fraction of immunserum was isolated by affinity chromatography on Protein G-Sepharose.
Presentation
Screw-capped clear glass vial containing 1.0 mg of purified IgG lyophilized from 1 mL PBS with 200 mM mannitol, pH 7.5.
Reconstitution
Add 1 mL of filtered deionized water. Agitate gently for 5 minutes.
Storage and Stability
Store unopened vials at 2 - 8 °C until the expiration date shown on label.
Store reconstituted antibody in aliquots at -20 °C or colder. Stable for at least 6 months; avoid repeated freeze and thaw cycles.
Applications
ELISA
The antibody can be used as capture or detection antibody in ELISAs.(3)
Western Blot
The antibody can be used for immuno-blotting (4).
Immunohistochemistry
The antibody can be used for immunohistological staining of frozen (5,6) and formalin-fixed, paraffin-embedded tissue sections (7).
Category: Research use only
Type: Antibody
Product Availability: Worldwide
Manufacturer: ImmBioMed GmbH & Co KG, Germany
For more information please click .pdf icon below.
goat anti-human PAI-2 IgG
Cat.No. ADG74
Article no.: 938525
Unit: 1 mg
Code: ADG74
Manufacturer: ImmBioMed GmbH & Co. KG
References
- Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Casslén B et al., Eur J Cancer. 1994;30A(9):1302-1309.
- Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Lecander I et al., Br J Haematol. 1984 Jul;57(3):407-412.
- Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy. Estellés A et al., Thromb Haemost. 1990 Oct 22;64(2):281-285.
- Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Reinartz J et al., Exp Cell Res. 1996 Feb 25;223(1):91-101.
- Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. Schaefer BM, et al., Autoimmunity. 1996;23(3):155-164.
- alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Schaefer BM et al., Arch Dermatol Res. 1996 Mar;288(3):122-128
- Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. Ferrier CM et al., J Histochem Cytochem. 1998 Apr;46(4):469-476.